Drugs Xagena
The European Commission has approved the use of Xadago ( Safinamide ) for the treatment of idiopathic Parkinson’s disease. Xadago has been approved for mid-to late-stage fluctuating patients as add- ...
The FDA ( U.S. Food and Drug Administration ) has approved Xadago ( Safinamide ) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking Levodopa / Carbidopa and ...
Safinamide mesilate, discovered and developed by Newron Pharmaceuticals ( Milan, Italy ), is a selective monoamine oxidase B ( MAO-B ) inhibitor, which reduces the degradation of excreted dopamine, he ...
